Researchers discuss MET gene alterations in lung cancer, focusing on targetable changes like exon 14 skipping mutations and fusions. Capmatinib and Crizotinib show promise as treatments, but drug resistance remains a challenge. Various MET tyrosine kinase inhibitors are in development or under evaluation for potential combination therapies.